Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- MSD Files Keytruda Plus Chemo for Endometrial Cancer in Japan
April 15, 2024
- Wholesaler Purchase Prices of Unprofitable Drugs on Upward Trend after FY2024 Revision
April 12, 2024
- Japan Autoimmune Drug Market Likely to Top 1 Trillion Yen in 2033: Fuji Keizai
April 12, 2024
- Smallpox Drug TPOXX Filed in Japan after Govt Request
April 12, 2024
- Moderna, Tohoku Biobank Start Epidemiology Study on Latent Viruses
April 12, 2024
- ASKA’s Birth Control Pill Makes Mark in Japan PIII Study
April 12, 2024
- Moderna Plots Successive Launches in Japan, Updated COVID Jab by Fall: Medical Chief
April 11, 2024
- GSK, Nagasaki University Begin Large-Scale Epidemiological Study on RSV
April 11, 2024
- Teijin Out-Licenses Narcolepsy Drug to France’s Bioprojet
April 11, 2024
- AZ/Fujifilm Develop Chemoradiotherapy Database for Lung Cancer
April 10, 2024
- Hypertension Therapy App Might Reduce Use of Antihypertensives: CureApp
April 10, 2024
- Otsuka/Lundbeck Seek PTSD Nod for Rexulti in US
April 10, 2024
- US FDA Grants Orphan Exclusivity for ALS Drug Radicava ORS
April 10, 2024
- R&D Jobs Make Up 40% of Pharma New Grads Hires This Spring, Sales Reps Only 20%: Poll
April 9, 2024
- Toray Nets Positive Preclinical Data in Polymer-Conjugated Cancer Drug
April 9, 2024
- Renalys Submits IND for Japan PIII Study of IgA Nephropathy Drug
April 9, 2024
- Janssen Files Amivantamab Plus Lazertinib for NSCLC in Japan
April 9, 2024
- Enhertu Nabs Pan-Tumor Indication in US: Daiichi Sankyo
April 9, 2024
- GSK Japan Shooting for 80% Goal for Paid Paternity Leave in 2024
April 8, 2024
- Otsuka, Verily Join Forces to Run Mental Health Registry
April 8, 2024
ページ
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…